Platform to Patient

WuXi’s Laboratory Testing Division is a comprehensive integrated testing platform supporting customers across the full spectrum of their development efforts to deliver innovative medicines to patients.

At a Glance


R&D Sites in the US and China


Employees Globally


Global IND Packages Completed


Global NDA Packages Completed


Clinical Centers in China


Years GMP and GLP Lab Experience


Validated Methods for Bioanalysis

Integrated Testing Platforms

Preclinical Drug Development

WuXi IND (WIND) combines technical experience, program management and regulatory expertise to facilitate submission of your IND package.

Clinical Drug Development

The Laboratory Testing Division can carry your compound from early discovery all the way through clinical trials, providing consistent, streamlined support across the lifecycle of your project.

Medical Device Testing

WuXi’s medical device testing experts provide end-to-end regulatory and technical support to bring your medical devices to market.

End-to-End Services

Analytical Services

The Analytical Services Unit provides both early and late-phase analytical support, including integrated CMC services from IND to NDA and beyond.

Bioanalytical Services

Bioanalytical Services at the Laboratory Testing Division support in vitro ADME, discovery biology, PK, PD and discovery toxicology from NCE through IND.

DMPK Services

The Laboratory Testing Division provides comprehensive in vitro and in vivo ADMET solutions from high-throughput screening in discovery through drug development phases.

Toxicology Services

Our skilled team of toxicologists provide comprehensive safety assessments across a wide range of species and through various routes of administration.


We are pleased to welcome Guangcheng Zheng to our Analytical Services team

Read our thought leadership article “Creating Comprehensive Solutions through Laboratory Testing”

American College of Toxicology (ACT) 2018 Annual Meeting
November 4 – 7
West Palm Beach, FL

AAPS PharmSci 360 2018
November 4 – 8
Washington, DC